Baseline characteristics of patients
| . | t(8;21) . | inv(16) . | All . |
|---|---|---|---|
| Number of cases | 230 | 215 | 445 |
| HTS platform, n (%) | |||
| Lille | 106 (46) | 109 (51) | 215 (48) |
| MLL | 124 (54) | 106 (49) | 230 (52) |
| Age, median (range), y | 41 (2-80) | 43 (1-81) | 42 (1-81) |
| Sex, n (%) | |||
| Male | 124 (54) | 127 (59) | 251 (56) |
| Female | 106 (46) | 88 (41) | 194 (44) |
| WBC, median (range), × 109/L (n = 405) | 9.6 (1.3-170) | 32.1 (0.1-351) | 15.0 (0.1-351) |
| ACA, n (%) (n = 406) | |||
| Absent | 66 (29) | 110 (61) | 176 (43) |
| Present | 159 (71) | 71 (39) | 230 (57) |
| Induction outcome, n (%) | |||
| CR | 220 (96) | 204 (95) | 424 (95) |
| Early death | 6 (2) | 11 (5) | 17 (4) |
| Primary induction failure | 4 (2) | 0 (0) | 4 (1) |
| HSCT in first CR, n (%) | 24 (10) | 22 (10) | 46 (10) |
| Median follow-up, y | 5.0 | 4.5 | 4.7 |
| . | t(8;21) . | inv(16) . | All . |
|---|---|---|---|
| Number of cases | 230 | 215 | 445 |
| HTS platform, n (%) | |||
| Lille | 106 (46) | 109 (51) | 215 (48) |
| MLL | 124 (54) | 106 (49) | 230 (52) |
| Age, median (range), y | 41 (2-80) | 43 (1-81) | 42 (1-81) |
| Sex, n (%) | |||
| Male | 124 (54) | 127 (59) | 251 (56) |
| Female | 106 (46) | 88 (41) | 194 (44) |
| WBC, median (range), × 109/L (n = 405) | 9.6 (1.3-170) | 32.1 (0.1-351) | 15.0 (0.1-351) |
| ACA, n (%) (n = 406) | |||
| Absent | 66 (29) | 110 (61) | 176 (43) |
| Present | 159 (71) | 71 (39) | 230 (57) |
| Induction outcome, n (%) | |||
| CR | 220 (96) | 204 (95) | 424 (95) |
| Early death | 6 (2) | 11 (5) | 17 (4) |
| Primary induction failure | 4 (2) | 0 (0) | 4 (1) |
| HSCT in first CR, n (%) | 24 (10) | 22 (10) | 46 (10) |
| Median follow-up, y | 5.0 | 4.5 | 4.7 |
ACA, additional cytogenetic alteration.